CombiMatrix Appoints Robert E. Hoffman to Board of Directors

CombiMatrix Appoints Robert E. Hoffman to Board of Directors

Veteran Healthcare, Finance Executive is CFO of Arena Pharmaceuticals, Inc.

IRVINE, Calif., July 17, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing
services for developmental disorders and cancer diagnostics, today announced
that veteran healthcare and finance executive Robert E. Hoffman has been
appointed to the Board of Directors, effective immediately. Hoffman, 47, fills
a current vacancy on the Board, which with his appointment is now made up of
seven directors.

Hoffman has broad financial experience in the biopharmaceuticals sector. He is
Senior Vice President, Finance and Chief Financial Officer of Arena
Pharmaceuticals, Inc. (Nasdaq:ARNA), a San Diego-based biopharmaceutical
company focused on discovering, developing and commercializing novel drugs
that target G protein-coupled receptors, or GPCRs, to address unmet medical
needs. BELVIQ^® (lorcaserin HCl), Arena's internally discovered drug, is
approved in the United States, and is under review for regulatory approval in
additional territories.

Since joining Arena in 1997, Hoffman has served in various finance and
accounting roles that have involved Arena's IPO, follow-on financings and
transition to a commercial-stage company. In addition, he has served as CFO of
Polaris Group, a privately held drug development company. Hoffman is a member
of the business and financial advisory board of La Jolla, CA-based Innovus
Pharmaceuticals, a publicly-traded emerging pharmaceuticals company.

"We are pleased to welcome Robert to our Board at this very important time for
CombiMatrix," said R. Judd Jessup, Chairman of the CombiMatrix Board of
Directors. "We see the prenatal molecular diagnostic market is growing
rapidly, in particular chromosomal microarray analysis, in which we
specialize. Robert's financial expertise will be especially useful as we seek
to expand into major markets throughout the U.S. and continue to establish
strategic corporate partnerships with regional pathology groups. We look
forward to working closely with Robert during these important stages of our
expected growth."

Hoffman serves on the Financial Accounting Standards Board's Small Business
Advisory Committee and the steering committee of the Association of Bioscience
Financial Officers. He is also a member and former director and president of
the San Diego Chapter of Financial Executives International. Hoffman has a
bachelor's degree in business administration from St. Bonaventure University
and is licensed as a C.P.A. (inactive) in the state of California.

About CombiMatrix Corporation

CombiMatrix Corporation provides valuable molecular diagnostic solutions and
comprehensive clinical support for the highest quality of care – specializing
in miscarriage analysis, prenatal and pediatric healthcare. CombiMatrix offers
comprehensive testing services for the detection of abnormalities of genes at
the DNA level beyond what can be identified through traditional
technologies.The Company performs genetic testing utilizing microarray, FISH,
PCR and G-Band chromosome analyses. Additional information about CombiMatrix
is available at or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995.These statements are based upon our current expectations, speak only
as of the date hereof and are subject to change.All statements, other than
statements of historical fact included in this press release, are
forward-looking statements.Forward-looking statements can often be identified
by words such as "see," "anticipates," "expects," "intends," "plans," "goal,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "could," "potential," "continue," "ongoing," "objective," similar
expressions, and variations or negatives of these words and include, but are
not limited to, statements regarding our growth, the growth of our markets,
our expansion into major markets and our strategic corporate
partnerships.These forward-looking statements are not guarantees of future
results and are subject to risks, uncertainties and assumptions that could
cause our actual results to differ materially and adversely from those
expressed in any forward-looking statement.The risks and uncertainties
referred to above include, but are not limited to:market acceptance of our
services; the rate of our growth and the growth of our markets; our ability to
successfully expand the base of our customers and strategic partners, add to
the menu of our diagnostic tests in both of our primary markets, develop and
introduce new tests and related reports, optimize the reimbursements received
for our testing services, and increase operating margins by improving overall
productivity and expanding sales volumes; our ability to successfully
accelerate sales, allow access to samples earlier in the testing continuum,
steadily increase the size of our customer rosters in both developmental
medicine and oncology; our ability to attract and retain a qualified sales
force; rapid technological change in our markets; changes in demand for our
future products; legislative, regulatory and competitive developments; general
economic conditions; and various other factors.Further information on
potential factors that could affect our financial results is included in our
Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other
filings with the Securities and Exchange Commission.We undertake no
obligation to revise or update publicly any forward-looking statements for any
reason, except as required by law.

CONTACT: Company Contact:
         Mark McDonough
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624
         Media Contact:
         Len Hall
         VP, Media Relations
         Allen & Caron
         Tel (949) 474-4300
         Investor Relations Contact:
         John Baldissera
         BPC Financial Marketing
         Tel (800) 368-1217

CombiMatrix Corporation
Press spacebar to pause and continue. Press esc to stop.